Information for Healthcare Providers
Questions about referring a patient?
Referrals from other health care providers are welcome. Every effort will be given to honor the relationship established with the referring provider and work collaboratively. If you refer a patient you will be involved and informed of treatment with updates and reports of treatment response. You may adjust psychotropic medication and continue with psychotherapy during the treatment period and provide feedback on the progress and effect of treatment. Often patients remitting from depression will have the energy and motivation to utilize therapy in more effective ways.
If you have a patient that you feel may be appropriate for TMS therapy and wish to discuss the patient with Dr Hayden please call the office and identify yourself as a treatment provider. You may also refer directly by using the optional fax form and your request will be followed up promptly.
Please consider dropping by to see the TMS suite, see a demonstration of treatment and visit with Cindy Duvall RN and Dr Hayden- just call first to arrange a time.
Based on the 2010 APA (Americal Psychiatric Association) the guidelines changed to include NeuroStar TMS Therapy as a second-line treatment modality
Click here to see the APA’s 2010 Best Practices Treatment Guide for Depression (this guide is 2 pages, be sure to scroll down to see 2nd page)
In May of 2010, The National Institutes of Health (NIH) published the results of their study on TMS therapy titled – Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder -A Sham-Controlled Randomized Trial. The objective of this study was to test whether daily left prefrontal rTMS safely and effectively treats major depressive disorder(MDD). Approximately 860 outpatients were screened, yielding 199 antidepressant drug–free patients with unipolar nonpsychotic major depressive disorder. In this National Institutes of Health–sponsored, industry-independent trial, high-intensity rTMS for at least 3 weeks was significantly more likely than sham rTMS to induce remission in antidepressant medication–free patients with moderately treatment-resistant unipolar MDD. The results of this study suggest that prefrontal rTMS is a monotherapy with few adverse effects and significant antidepressant effects for unipolar depressed patients who do not respond to medications or who cannot tolerate them.